15-Epi-lipoxin A(4) inhibits the progression of endometriosis in a murine model.
OBJECTIVE
To examine the pro-resolution actions of 15-epi-lipoxin A(4) (LXA(4)) on endometriotic lesions, on the concentrations and activities of matrix metalloproteinases (MMP-2 and MMP-9) in murine endometriosis.


METHODS
Prospective, vehicle-controlled experimental study.


METHODS
Animal research facility.


METHODS
BALB/c mice.


METHODS
Endometriosis (EM) was induced in 30 mice. Fifteen of them were administered LXA(4) for 24 days (LXA(4) group), whereas the other 15 served as a control group (EM group). Another 15 sham-operated mice (sham-operated group) were treated with vehicles.


METHODS
The weight of the endometriotic lesions was measured. The concentrations, mRNA, and activities of MMP-2 and MMP-9 were determined by enzyme-linked immunosorbent assay, quantitative real-time polymerase chain reaction, and gelatin zymography, respectively.


RESULTS
Compared with EM group, the weight of the endometriotic lesions was decreased, the concentrations of MMP-2 and MMP-9 dropped, the mRNA levels of MMP-2 and MMP-9 in the peritoneal fluid cells and the endometriotic lesions were reduced, and the activities of MMP-2 and MMP-9 were inhibited in the LXA(4) group.


CONCLUSIONS
LXA(4) may inhibit the progression of endometriosis possibly by lowering the concentrations and the activities of MMP-2 and MMP-9.
Chen
Qiong-Hua
QH
Department of Obstetrics and Gynecology, Tongji Hospital of Tongji Medical college of Huazhong University of Science & Technology, Wuhan, People's Republic of China.
Zhou
Wei-Dong
WD
Pu
De-Min
DM
Huang
Qian-Sheng
QS
Li
Tian
T
Chen
Qing-Xi
QX
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000494:pharmacology*; D001202:Ascitic Fluid / Q000166:cytology / Q000201:enzymology; D004195:Disease Models, Animal; D018450:Disease Progression; D015536:Down-Regulation; D004715:Endometriosis / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D004717:Endometrium / Q000187:drug effects* / Q000201:enzymology / Q000473:pathology / Q000637:transplantation; D004797:Enzyme-Linked Immunosorbent Assay; D004971:Estrus; D005260:Female; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D007274:Injections, Intraperitoneal; D044045:Lipoxins / Q000008:administration & dosage / Q000494:pharmacology*; D020778:Matrix Metalloproteinase 2 / Q000235:genetics / Q000378:metabolism; D020780:Matrix Metalloproteinase 9 / Q000235:genetics / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D012333:RNA, Messenger / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction
D000894:Anti-Inflammatory Agents, Non-Steroidal; D044045:Lipoxins; D012333:RNA, Messenger; C040527:lipoxin A4; D020778:Matrix Metalloproteinase 2; C522362:Mmp2 protein, mouse; D020780:Matrix Metalloproteinase 9; C501830:Mmp9 protein, mouse